Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 9/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CETP | P11597 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13428476 | 0.84 | L3MBTL1 (0.40) | L3MBTL1MEN1MAPTKMT2ALMNA | |
| SCHEMBL13428802 | 0.83 | P2RY12 (0.59) | P2RY12L3MBTL1MAPTLMNA | |
| SCHEMBL3228333 | 0.83 | ALDH1A1 (0.41) | L3MBTL1MAPTKMT2ALMNA | |
| SCHEMBL13428812 | 0.82 | P2RY12 (0.51) | P2RY12L3MBTL1MEN1MAPTCASP3 | |
| SCHEMBL13428569 | 0.80 | AOC3 (0.41) | L3MBTL1MEN1MAPTKMT2ALMNA | |
| SCHEMBL3217492 | 0.78 | P2RY12 (0.48) | P2RY12L3MBTL1MEN1MAPTCASP3 | |
| SCHEMBL13429148 | 0.77 | HDAC6 (0.46) | MAPT | |
| SCHEMBL3233534 | 0.75 | P2RY12 (0.46) | P2RY12L3MBTL1MEN1MAPTCASP3 | |
| SCHEMBL13428798 | 0.74 | KDM4E (0.51) | P2RY12L3MBTL1MEN1KMT2A | |
| SCHEMBL13428810 | 0.74 | ALDH1A1 (0.46) | P2RY12L3MBTL1MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | HDAC1, HDAC11, HDAC2 | P2RY12 4610/4885L3MBTL1 1127/4885CETP 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.